view great
best growth profil large-cap
initi coverag vertex outperform rate tp
among coverag vertex top pick larg cap biotech
attract revenu earn growth profil group vertex
market leader develop commerci therapeut treat cystic
fibrosi cf rare genet lung diseas compani product
standard-of-car cf patient global substitut
minim competit exist given long patent live
under-valued basi although share appear expens
forward p/e-basi vs larg cap biotech major
pharma look inexpens forward-earnings-
growth basi vertex vs larg cap biotech
major pharma see upsid opportun
share rel peer next month base
best posit among peer look vertex vi -- vi coverag
univers think vertex base busi grow driven
symdeko vertex strong cf pipelin vertex acquir
strength need engag secur growth
pipelin beyond cf launch tripl current pipelin focu
compani earlier pipelin work pain antitrypsin
hemoglobinopathi could provid addit upsid model
valuat risk valu share use dcf analysi support
pt assum wacc termin valu growth rate
risk commerci product sale fail meet expect intellectu
properti patent key product challeng gener enter earlier
anticip clinical/develop clinical-stag asset fail trial regulatori
regulatori author delay fail approv product external/market
valuat metric
number share
price month
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
vertex engag develop commerci
therapeut rare diseas includ main franchis cystic
scenario assum dcf valu
share cut sg respect also
assum regulatori approv tripl combin
us ou assum posit proof-of-concept data
next gener cf asset also assum
posit data updat pipelin asset
grey sky scenario model less credit triplet
lower probabl success reflect increas risk
compani face meaning setback
 close
tabl content
invest summari thesi
guidanc consensu expect
cystic fibrosi franchis drive best-in-class revenu earn growth
reimburs challeng uk franc
vertex pipelin beyond cf pain crispr partnership
small molecul correct
pain
partnership crispr therapeut
holt view vertex
cs peer relationship vertex
cystic fibrosi overview vertex medicin
invest summari thesi
vertex attract revenu earn growth profil among biotech
pharma peer vertex commercial-stag biotechnolog compani focus
develop disease-modifi therapi treat cystic fibrosi cf compani
current market cf drug kalydeco orkambi symdekowhich address
global cf popul small molecul drug pill correct
protein defect found patient cf within next year vertex like
approv medicin base posit phase clinic data refer tripl
combin allow compani address nearli cf patient
estim ww believ vertex like remain
leader cf space could take nearli share real competitor
drug near-term beyond cf compani work develop therapi
rare diseas includ gene edit hemoglobinopathi blood
disord pleas see industri report detail larg cap biotech sector
excel revenu earn growth potenti compar peer vertex
revenu earn growth unlik larg cap biotech major pharma peer
ep compound-annual-growth-rate sale compound-annual-growth-rate estim compar
larg cap biotech ep compound-annual-growth-rate sale pharma ep compound-annual-growth-rate
sale compound-annual-growth-rate asid select smid cap biotech name
name broader biopharma univers screen well vertex initi
coverag outperform rate pt base view vertex
differenti growth profil drive near-term cash flow also allow
reinvest busi support long-term growth
target price base dcf analysi assum wacc
termin growth rate fulli dilut share outstand vertex
commerci product standard-of-car cystic fibrosi patient around
world substitut epidemiolog cf well understood
larg patient registri exist mani compani major market allow us
quantifi address market vertex year experi commerci
cf portfolio develop degre expertis interact intern
regulatori agenc support patient access vertex ip protect commerci
exclus expect persist throughout forecast period see minim
near-term competit threat account risk-mitig factor valuat
assumpt via wacc
risk commerci risk much valuat predic vertex success
commerci cf drug world-wide failur meet exceed consensu
expect could neg affect share intellectu properti risk vertex
commerci busi protect patent allow compani sell therapi
without competit patent deem invalid gener
competitor could take signific market share clinic development risk
valuat base drug yet shown success
clinic trial trial fail vertex share could neg impact
regulatori risk valuat base cash flow drug
yet approv regulatori author fda ema fail approv asset
vertex share could neg impact regulatori bodi could also pull
market author vertex product shown unsaf extern
market risk remain volatil sector affect extern
factor includ drug price legisl intellectu properti law healthcar polici
overal economi neg polici develop and/or weaken economi
cf revenu drive next year expect cf revenu drive free-
cash flow vertex expect grow compound-annual-growth-rate estim
non-gaap ahead consensu includ risk-adjust sale uk
franc model help drive long-term above-consensu expect
think vertex get closer reimburs key territori could
immedi add revenu base see strength durabl franchis
vertex like real player cf near term abbvi cftr corrector
galapago unlik success develop data thu far inferior
forward price-to-earnings basi vertex share expens fail account
signific earn growth potenti forward basi share trade
discountsuggest addit upsid multipl expans vertex still
earli growth phase ep becam posit current cf-focus
iter compani drive rel high price-to-earnings vs peer vs
larg cap biotech pharma look
share basi price paid earn growth lower
peer across biotech pharma suggest
earn growth rel inexpens examin share sole basi
price-to-earnings fail fulli valu strength busi growth profil abil
compani invest pipelin whether cf rare diseas
tripl file full data guidanc revis reimburs agreement
england franc like drive upsid investor expect tripl
alreadi highw think addit upsid compani file
present full data set note day second tripl data set came
stock seen slight delay file vertex also typic
guid conserv could see guidanc revis cours
year drive upsid x-factor like drive upsid would
announc formal agreement nh england fund orkambi symkevi
non-north america trade name symdeko potenti tripl combin
approv uk largest concentr cf patient world approxim
world popul thu repres signific revenu
opportun formal agreement franc would also like drive share upsid
predict exactli agreement would reach think recent progress
vertex english govern posit indic agreement
uniqu approach model cf opportun quantifi potenti
opportun cf sale uk franc risk-adjust basi assum
increment sale territori base-cas assumpt
uk assum portfolio deal negoti includ orkambi symkevi
tripl end-us revenu somewhat higher
origin propos nh england vertex could accept assum
discount german price potenti reimburs begin franc
assum orkambi reimburs base-cas get sens much
current negoti focus asset risk-adjust basi po
calcul approxim revenu assum portfolio deal
reach could see revenu closer think reimburs
franc uk could provid meaning upsid long-term revenu
part consensu view cf franchis
non-cf pipelin remain interest call option limit data
risk/reward pipelin favor see limit valu reflect share price
antitrypsin defici pain focal segment glomerulosclerosi sickl
cell/beta thalassemia first program small molecul treat antitrypsin
defici remain earli clinic develop first molecul
transit clinic develop decemb pre-clin work present
compani seem ration view howev data pre-clin
model pain program target demonstr proof-of-concept
acut inflammatori neuropath painbut program earli
compani still engag dose-find studi novel non-opioid pain program
taken signific amount time develop see regeneron fasinumab pfizer/lilli
tanezumab although differ target differ type pain remain cautiou
see continu efficaci data importantli long-term safeti data
crispr partnership remain earli one patient dose
beta thalassemia highlight first applic gene edit
clinic trial set compani plan dose second patient treat
sever sickl cell diseas rel easier ex-vivo outsid
bodi approach clinic data support efficaci human patient make
difficult us formal assign valu program still fda recent grant
program track design could help facilit develop regulatori
review think risk/reward remain favor program like little-to-
valu reflect current share price
next month expect continu progress commerci front
cf development updat tripl potenti updat earlier
pipelin commerci progress translat cash flow upsid increas
guidanc like impact driver share near-term also
expect detail surround regulatori file tripl decis
tripl combin bring forward full data set potenti fall nacfc
meet could also support stock would like see long-term data around
durabl efficaci het-min homozyg patient beyond cf
updat potenti initi data patient treat could provid
vertex thesi predic busi develop believ
compani immedi need gilead buy near-term pipelin
upsid howev target busi develop give vertex access novel
treatment modal could seen posit investor think anyth
compani could expand gene therapi dri powder larger
deal would give access platform
vertex rel strong earn modest revenu beat non-
gaap ep beat notabl symdeko strong recent launch
germani compani remain earn growth mode encourag
progress commerci cf portfolio drug vertex reiter revenu
guidanc call event reimburs deal uk franc
expect would updat
near-term outlook posit upsid potenti driven continu
commerci excel think updat guidanc revis could help drive
upsid share near-term coupl like updat file full data
set tripl combin would like support stock rel peer
long term outlook believ cf busi durabl opportun
pipelin expans cf franchis could protect least
could provid vertex extrem durabl cash flow expect sort return
 addit invest busi long term continu
drive revenu earn growth like lean oper model focu rare
diseas posit vertex strongli rel peer
credit suiss view vertex rel peer rel coverag univers
believ vertex base busi strongest potenti deliv consist
return sharehold view compani futur cash flow less riski
compar larg cap biotech peer due lower competit long patent life
grow market cf space contrast gilead declin hepat viru
market increasingli competit spinal muscular atrophi sma multipl
sclerosi ms busi project grow cash flow long term support
pipelin diversif vertex interest pipelin could eventu translat
diversifi revenu although earlier stage similar vertex
also view buyer strength need transact maintain cash flow
vertex signific capac acquir new asset advantag
select time compar gilead
guidanc consensu expect
guidanc conserv beatabl balanc think
guidanc cf franchis conserv beatabl see figur current
compani expect cf franchis sale impli growth
sale midpoint among attract larg cap biotech major pharma
note vertex take conserv approach guidanc specif
exclud sale territori formal reimburs agreement
seen consensu estim come recent thu revenu estim
remaind slightli still high end guidanc rang
non-gaap ep estim consensu lower expens tax
asid larg bump sale agreement england franc
discuss greater detail later section agreement smaller territori orkambi
symdeko could produc meaning upsid cf patient repres least
per year revenu compani guidanc suggest non-gaap effect tax rate
cash tax estim use rate
calcul non-gaap ep even though cash tax lower year estim
non-gaap ep higher factset consensu believ consensu
undervalu potenti addit upsid cf franchis
high capac transact immin need vertex signific room acquir
healthi cash balanc outstand debt project capac
figur compani could take debt vertex
better posit compar gilead vertex need
acquir due grow cash flow cf franchis vertex less
pressur undergo acquisit stabl base busi vertex market leader
cf drug long patent life believ vertex undergo
large-scal compani could undergo smaller transact acquir early-
stage asset diversifi pipelin compani histori develop earlier
drug rather buy late-stag bolt-on asset estim vertex capac even
larger
vertex price-to-earnings high upsid
vertex price-to-earnings may high compani still earli stage
profit non-gaap ep neg growth
profil vertex earn revenu perspect
unlik larg cap biotech major pharma without
level pipelin risk mani smid cap biotech name
vertex low rel ratio larg cap
biotech peer pharma
project earn growth vertex seem rel cheap
peer even current trade level high price-to-earnings
vertex forward price-to-earnings high warrant continu multipl
expans cash flow earn potenti fairli valu
current valuat like littl upsid surpris
consensu expect cf franchis suggest cash
flow base busi fulli reflect stock price
rel expens vertex share reflect long-term ep
growth prospect potenti multipl compress absent
signific pipelin develop limit upsid
vertex one best earn revenu growth profil larg cap biotech pharma also exce expect
broader market high forward price-to-earnings function recent becom profit look share forward
basi rel cost earn growth far less pharma larg cap biotech peer think like upsid
surpris number territori forg reimburs agreementsespeci england franc pipelin free call
option like current valu share
ii ou reimburs approv product
vertex continu expand access ou market
product includ symdeko/symkevi like
approv tripl combin therapi addit bull
scenario vertex gain broad reimburs tougher
govern name england uk franc essenti
vertex abl sell commerci therapi patient ww
limit access barrier full govern support/fund
vertex continu experi difficulti obtain ou
reimburs notabl england uk uk nh continu
reject reimburs indic believ cost high
countri cf popul take similar stanc uk
reject perceiv high-cost vertex cf therapi
guidanc assum sale countri without
reimburs agreement consensu expect could
valu territori england franc canada
set unrealist expect
follow recent interact vertex execut uk parliament think reimburs agreement nh england
get closer neither say sure deal would ink addit insight discuss
franc agreement would provid addit upsid think revenu england franc essenti support
near-term thesi continu progress territori tripl combin like suffici support stock
come year current level earn growth rel less expens end includ risk-adjust sale territori
believ point vertex respect govern come agreement
valu non-cf pipelin
vertex diversifi pipelin high-valu therapeut
area like gener near-term share upsid
like posit data updat vertex use
approach rapidli develop small molecul drug treat
compani cfallow quick clinic trial
approv proof concept data pain program
like support success phase could support
credit share price
pipelin beyond cf immatur like over-valu
market program nascent recent enter clinic
develop vertex success rapidli develop
novel cf asset success differ
indic guarante compani much work
pain program remain difficult area develop
drug includ dose find safeti studi ex-vivo crspr
applic earli riski assign real valu
despit dose two patient
view non-cf pipelin free call option limited-to-no valu ascrib pain crispr program
need see clinic data fulli comfort program risk/reward remain favor confid vertex
abil quickli success develop novel drug evidenc shift hcv cf driven intern innov could see
credit given program crispr beta-thalassemia sickl cell diseas program rel patient
figur vertex market pipelin
focusassetindicationstatuskalydeco ivacaftor gate mutationsmarketedorkambi lumacaftor ivacaftor homozyg marketedsymdeko tezacaftor ivacaftor homozyg residu cftr mutationmarketedtripl combin tezacaftor ivacaftor heterozyg cftr function het-min phase correctorphas deuter ivacaftor cftr potenti daili regimen phase cell diseasebeta thalassemianeuropath painacut antitrypsin deficiencyphas segment glomerulosclerosispreclinicalcyst charl martineau pm univers toronto figur total revenu cs vs consensu
figur vertex catalyst
figur forward price-to-earnings comparison vertex vs larg cap biotech
revenu total revenu ww cstotal revenu ww cagrc ep ep csep cagrc combin cystic top-line combin cystic fibrosismolecul select nda fibrosisfda approv age gene-edit sickl cell anemiafirst patient combin cystic fibrosisnda combin cystic fibrosisful data present potenti nacfc fibrosisema submiss age follow bunionectomyphas dose rang studi pain mechanismpain non opioid initi clinic gene-edit beta thalassemiaupd initi recruit antitrypsin deficiencyupd first molecul clinic segment glomerulosclerosispotenti clinic clinic develop second pain small molecul antitrypsin deficiencyclin develop second next-gener corrector cystic fibrosisphas proof-of-concept studi qd regimen cystic fibrosisphas proof-of-concept studi combin cystic fibrosisfda approvalearli combin cystic fibrosis regulatori submiss charl martineau pm univers toronto
figur forward price-to-earnings comparison vertex vs larg cap biotech averag
one-year price target base base-cas dcf analysi
assum wacc termin growth rate fulli dilut share
outstand vertex commerci product standard-of-car cystic
fibrosi patient around world substitut epidemiolog
cf well understood larg patient registri exist mani compani major
market allow us quantifi address market vertex year
experi commerci cf portfolio develop degre expertis
interact intern regulatori agenc support patient access vertex ip
protect commerci exclus expect persist throughout forecast
period see minim near-term competit threat account risk-
mitig factor valuat assumpt via wacc
forecast cash flow account known expect product launch
patent expir competit threat current portfolio pipelin beyond
forecast period appli termin growth rate cash flow expect vertex
continu invest life-cycl manag cf portfolio busi
develop effort success gener increment revenu rate greater
eros long-term
sensit analysi suggest valuat rang across variou termin
growth discount rate base case price target repres premium
vertex recent close price figur
dcf sensit analys sensit analysi help support valuat
look differ wacc tvgr figur assum lower growth tv
still see dcf valuat higher current share price
figur dcf sensit wacc tvgr varianc per share price
scenario scenario assum dcf valu
share cut sg respect also assum
regulatori approv tripl combin us ou
assum posit proof-of-concept data next gener cf asset
also assum posit data updat pipelin asset
gene-edit system furthermor assum continu growth market cf
grey scenario grey scenario model less credit
triplet lower probabl success reflect increas risk
compani face meaning setback scenario assum tripl combin
gain regulatori approv assum neg proof-of-concept
data next gener cf drug pipelin asset
also assum slower-than-anticip sale market cf drug kalydeco
discount analysi usd analysiskalydeco homozyg residu function valu growth rate tripl combin het-min cf opportun ex kalydeco unalloc cf opportun ex kalydeco unalloc revenu share opex tax stock base increas /decreas tripl capit cf cf free tv total equiti share current fulli dilut share price charl martineau pm univers toronto
commerci risk sale kalydeco orkambi symdeko/symkevi tripl
combin begin base dcf valuat sale
wors consensu expect could see vertex share pressur
unexpect success competitor develop novel cystic fibrosi medic
intellectu properti ip risk much vertex commerci busi base
small molecul asset limit patent life gener manufactur
success challeng vertex key patent signific portion
compani revenue-bas may risk loss major patent either
us ou could neg affect vertex share price
clinic develop risk valuat share upsid
potenti base outcom clinic trial vertex late-stag
asset shown clinic ineffect unsaf would expect neg
pressur vertex share
regulatori risk food drug administr fda european medicin
agenc ema regulatori bodi approv requir vertex
market sell therapeut delay outright reject approv
investig asset could neg impact futur cash-flow
valu vertex share fda ema could revok market
author market product due safeti efficaci concern
demonstr post-market set
external/market risk biotechnolog remain volatil sector
affect extern factor includ drug price legisl intellectu properti
law healthcar polici overal economi neg polici develop
and/or weaken economi could impact vertex share price
cystic fibrosi franchis drive best-in-class
revenu earn growth
posit vertex share long-term abil cf
franchis drive revenu earn growth think share
appreci remain room upsid
vertex core busi develop commerci diseas modifi medicin
treat cystic fibrosi cf cf diseas impact multipl organ system mainli
impact abil airway maintain homeostasi water chlorid ion
patient cf thick sticki mucu build airway make difficult breath
patient also increas risk infect mucu trap pathogen
unabl move away airway vertex drug kalydeco orkambi
symdeko/symkevi upcom tripl combin treat underli caus
diseas genet defect dna code cftr cystic fibrosi
transmembran conduct regul proteinan essenti protein found surfac
cell allow free movement chlorid ion sale medicin form
valuat vertex share much known epidemiolog cystic fibrosi
thu impli model sale accuraci think sale
earn growth potenti fulli realiz consensu current valuat
think form basi posit thesi vertex share section
discuss think upsid overal cf franchis discuss view
product includ tripl combin discuss reimburs progress
ww ink agreement impact share core
posit share believ compani attract revenu
earn growth profil share may expens forward price-to-earnings basi
screen inexpens forward basissuggest upsid remain
abil grow earn
model cf market determin valu flow
model vertex cf market rel straightforward given epidemiolog provid
compani support cf foundat current model drug note
approv tripl could shift model penetr elig
cf patient without break drug current estim peg global cf
popul north america europ australia approxim patient
patient potenti address current futur ivacaftor-
base therapi assum base cf popul increas per year
base literatur suggest new case per
approv tripl combin therapi vertex abl treat nearli cf
patient ww outlin mani patient current address
type drug figur note use current approach protein fold
correct abl treat patient remain patient
treat current vertex therapi remain mutat consid
amen treatment potenti corrector cftr protein
mutat allow product protein nearli function fixabl
vertex drug compani would use gene therapy/edit repair
dna mutat allow function cftr protein product
detail moa mechan action aka drug work kalydeco
ivacaftor orkambi lumacaftor/ivacaftor symdeko/symkevi tezacaftor/ivacaftor
tripl ivacaftor/tezacaftor see cystic fibrosi section
appendix link section
also assum vertex enjoy exclus approxim us
ousthi potenti patent life region see
figur vertex drug earlier patent expir could see
patient eventu shift tripl combin therapi long-term better efficaci vs
doublet therapi still review key patent expir approv drug
highlight potenti risk franchis
figur cystic fibrosi patient vertex drug
rafeeq et al cystic fibrosi current therapeut target futur approach transl
total charl martineau pm univers toronto
figur vertex drug patent expir us eu
kalydeco first vertex cf therapi approv patient
gate mutat initi fda approv patient mutat
gener cftr cystic fibrosi transmembran conduct regul protein
cellular surfac airway narrow effect allow sodium ion
move freeli kalydeco act help maintain open channel allow movement
sodium ion airway tissu ensur mucu line airway
thin free flow vs thick sticki estim approxim
patient address kalydeco combin gate
mutat kalydeco smallest contributor cf model peak sale
approxim ww assum rel high penetr us ou
market us assum approxim patient kalydeco
therapi increas slightli y/i base overal cf popul growth
model us net price approxim per patient per year annual price
increas assum gross list wac wholesal acquisit cost box
tabl enough drug week twice-a-day therapi bid assum
gross net discount approxim wac per discuss
compani high complianc life-sav diseas modifi therapi
figur detail us kalydeco revenu model estim us
patent ivacaftor expir may sourc evalu pharma
ou assum approxim patient treat kalydeco
increas y/i due higher penetr well gener increas base patient
popul assum discount wac price ou price
approxim annual per patient base publicli avail gross price
germani assum addit gross-to-net discount complianc
product/ drug candidatestatu us patent project expir statu eu patent project expir kalydecogr symkevigr tezacaftor/ ivacaftorpend tezacaftor/ ivacaftorpend certain european countri grant supplementari protect certif kalydeco expir certain european countri grant supplementari protect certif orkambi expir intend appli certain european countri supplementari protect certif symkevi expect expir market patient patient elig acqusit cost wac week treatment week period one wac- cost per patient per unadjust revenu kalydeco charl martineau pm univers toronto
rate ou net cost per patient per year approxim figur
ou kalydeco build estim ou patent ivacaftor expir
decemb sourc evalu pharma includ sale franc uk
ou orkambi build vertex current formal reimburs
figur ou kalydeco revenu build includ franc uk patient
orkambi second vertex cf therapi approv patient homozyg
mutat cftr gene initi fda approv combin
therapi ivacaftor lumacaftor patient mutat cftr
protein surfac airway cftr protein produc ribosom
cell defect remov prior reach cell surfac patient amen
kalydeco therapi protein cell defect patient need
therapi correct protein misfold cftr protein also help
keep channel open orkambi combin drug ivacaftor kalydeco
lumacaftor lumacaftor cftr corrector help promot correct fold
cftr protein follow construct ribosom transport cell
surfac ivacaftor help keep channel open cftr protein reach cell
allow free flow sodium ion epidemiolog estim
approxim patient address market homozyg
mutat age year older current approv indic
given larger popul elig orkambi reimburs
challeng especi england franc current debat singl payer
govern orkambi efficaci rather valu detail latest
saga vertex nh england also franc later report given
import franc uk analyz potenti cf opportun
orkambi symkevi tripl combin whole see potenti
risk-adjust sale base case detail later
note patient elig orkambi also elig symdeko/symkevi
overview next thu assum high penetr homozyg
mutat popul us orkambi launch report
chest tight initi dose drug limit initi use caus
rel high discontinu among elig patient symdeko also approv treat
patient report side effect thu assum
increas penetr expens orkambi sale us
forecast patient treat orkambi net revenu
us orkambi wac approxim tablet bid twice-a-day dose
enough week treatment wac approxim assum
modest discount complianc net cost per patient per year
approxim assum annual price increas figur us
orkambi revenu build sever patent protect orkambi estim
key us patent expir begin late extend sourc
ex-u market patient patient elig unadjust revenu kalydeco charl martineau pm univers toronto figur us orkambi revenu build
ou reimburs orkambi remain challeng region
countri work vertex cover drug assum
approxim elig patient across europ canada australia
penetr rate increas peak slower rate
assum reimburs symdeko/symkevi regulatori approval/reimburs
tripl current exclud patient england franc anywher els vertex
formal reimburs reimburs orkambi england could
increas ou patient number peak sale discuss
impact reimburs england later section current ou price
assum gross per patient per year cost line public price
germani assum gross-to-net discount complianc
net price per patient per year reimburs england franc could
reduc averag net price believ reimburs agreement would price
orkambi lower threshold base nhss current view orkambi
expens figur ou orkambi revenu build exclud franc
uk opportun model separ two countri formal
reimburs ou estim patent expir decemb sourc evalu
figur ou orkambi revenu build exclud uk franc
symdeko/symkevi third vertex cf therapi approv patient
homozyg mutat cftr gene initi fda approv
februari one residu function mutat combin therapi ivacaftor
tezacaftor symdeko altern orkambi elig patient homozyg
residu function patient year older current
approv year old unlik orkambi ww approxim patient
year year residu function us assum
patient start orkambi homozyg discontinu
treatment due chest tighten new therapi homozyg
us market patient patient elig per week treatment treatment week period one gross list cost per patient per unadjust revenu orkambi market patient patient elig unadjust revenu orkambi charl martineau pm univers toronto
residu function patient treat symdeko patient age includ
risk-adjust sale assum approv snda submit late
patient approv
current assum net cost per patient per year base packag wac
tablet suppli assum gross-to-net discount
complianc take price increas unlik orkambi forecast revenu increas
time us see figur us symdeko revenu build
us assum patent exclus least may
ou symkevi ex-north america tradenam launch infanc vertex
still seek approv medicin territori similar us
eventu assum orkambi patient discontinu treatment unhappi
side effect profil start symkevi assum new patient
homozyg mutat residu function mutat eventu
start symkevi assum reimburs specif territori given challeng
orkambi assum patient therapi number
increas time assum countri come reimburs
agreement vertex
us symkevi approv patient year older
assum risk-adjust sale patient age approv approv
price perspect assum base annual gross price
line vertex asset gross-to-net discount complianc
germani rest world territori exclud uk franc assum modest
symkevi sale model outsid us assum
us market homozyg homozyg treat w/ orkambi homozyg treat w/ orkambi homozyg treat w/ orkambi homozyg treat w/ residu function patient total cf function function function address address address patient elig patient patient patient symdeko per week treatment treatment week period one gross list cost symdeko sale symdeko sale symdeko sale symdeko sale charl martineau pm univers toronto
homozygot treat orkambi increment residu function patient
treat symkevi take portfolio view cf franchis treatment
revenu captur model less concern specif product
assum equal net-revenu across orkambi symkevi tripl figur
ou symkevi revenu build includ germani
note estim could upwardli revis reimburs achiev
england franc ou patent-term inform applic
still like pend assum similar us
figur ou symkevi revenu build exclud uk franc
figur summari approv vertex therapi mutat group
year
year
reimburs challeng uk franc
reimburs orkambi remain challeng england recent interact
suggest side come back negoti tabl vertex
current nh uk nation health servic coverag kalydeco
patient therapi accord uk cystic
fibrosi trust registri report found kalydeco reimburs nh
agreement approxim per year annual per
patient price disclos estim nh pay per
patient per year signific discount price us germani despit
approv orkambi uk nh vertex fail reach agreement expand
coverag beyond name patient access program cover patient
view largest opportun remain orkambi symdeko eventu tripl
uk given medicin could address patient think
recent action uk parliament call vertex execut nh england
leader testifi signal polit pressur come reimburs agreement
increas predict agreement would forg think
side get closer brexit negoti could sidelin agreement vertex
recent brexit deadlin push octob could allow focu discuss
nh vertex pressur parliament
earlier propos reject vertex provid immedi expand
access kalydeco orkambi due amount discount addit
would provid immedi access symdeko follow licens beyond
asset propos detail would routin avail nh date
licens nh will pay cours year year
access product
letter ceo cystic fibrosi trust nh indic would increas
number patient receiv target therapi approxim
note includ tripl close uk popul would elig
therapi unclear propos deal would includ addit fund pend
approv tripl accord biocenturi link vertex estim deal would
price medicin approxim per patient per year
discount reimburs provid germani per year given
discrep valu medicin vertex reject deal nh
earli march link vertex ceo dr jeffrey leiden testifi front
uk parliament address impass compani nh
emphas arcan method assess valu medicin said vertex
could accept discount propos nh
problem weve paint think will take offer
discount england made us would actual say differ take
offer wont take cant
speak compani follow hear seem movement
still hard predict agreement would reach vertex nh
meet week parliamentari hear howev resolut yet
reach vertex think uk nation institut excel
bodi determin cost effect medicin uk need updat
methodolog assess long-term valu
addit direct negoti nh vertex talk
allow uk govern licens version drugsw see
unlik given difficulti manufactur drug believ
realist possibl near-term overal impass vertex nh like remain
near-term formal reimburs vertex product beyond kalydeco current
guidanc vertex includ reimburs product uk
model uk opportun given import uk reimburs vertex
includ risk-adjust sale patient follow mutat
think given avail orkambi symkevi like near-term approv
tripl combin regimen uk would like opt sort portfolio deal would
give nearli uk patient access therapi model allow user
chang assumpt around reimburs uk base case risk adjust
assum could agreement also assum three
product reimburs includ price approxim discount germani
adjust basi could see increment product revenu
adjust sale due uncertainti around formal reimburs
assum price less germani could see unadjust sale
still attract opportun figur uk base case
assumpt model output
recogn revenu number like repres
consensu expect think import quantifi given
could see addit revenu scotland late vertex
announc scottish medicin consortium accept orkambi
symkevi apprais link accept could see addit patient
therapi review process clinician abl appli access
therapi vertex scottish govern agre confidenti
discount drug revenu scotland current includ
revenu guidanc formal reimburs agreement yet final
could see guidanc updat scotland come board compani
exactli say long discuss take believ long
drawn process like england recent testimoni leiden note nh england
would agre deal scotland vertex would provid access therapi
patient abl receiv drug within week deal execut
figur cf revenu opportun uk
reimburs franc also challeng
vertex current distribut orkambi earli access program begin
despit on-going discuss french govern vertex
offici reimburs agreement book net revenu receiv sale
 compani mani reimburs french govern amount
collect earli access program final invoic price upon agreement
uk address product ex kalydeco sale product year vertex product receiv favor pppi discount german homozyg yet orkambi orkambi symkevi function symkevi patient address vertex reimburs vertex vertex product product sale ex kalydeco charl martineau pm univers toronto
reach back forth public uk
biocenturi articl link indic french govern offer reimburs
orkambi discount reject vertex negoti still
impass pressur french govern vertex cancel three plan phase
trial includ tripl combin
given similar challeng reimburs franc also includ risk
adjust sale model includ orkambi sale base case given
current name patient access program current vertex abl provid drug
patient unabl book revenu patient name patient access
program formal reimburs reach model assum
reimburs achiev orkambi mutat
could gener addit revenu risk adjust sale
similar uk vertex abl gain reimburs symkevi tripl
could see sale closer risk adjust basi unadjust
basi figur base-cas forecast franc
figur cf revenu opportun franc
despit headlin uk franc reimburs continu ou territori
current vertex enjoy full reimburs kalydeco orkambi countri
includ us australia denmark germani ireland sweden itali
overal compani product avail countriesthi includ name patient
access countri name patient access vs full reimburs includ
revenu guidanc could see near-term coverag scotland vertex recent
submit file fund approv scottish medicin consortium could open
access scotland recent investor call vertex indic countri
accept portfolio approach could includ faster access tripl approv
figur revenu upsid opportun full reimburs ou sale
figur ou cf revenu summari exclud uk franc
french address product ex kalydeco sale product year vertex product receiv favor pppi discount german homozyg yet orkambi orkambi symkevi function symkevi patient address vertex reimburs vertex vertex product product sale ex kalydeco sale excl uk homozyg residu function cf charl martineau pm univers toronto
highli innov medicin fulli realiz consensu estim
next key driver vertex file full data eventu approv
tripl combin treatment combin tezacaftor ivacaftor drug
symdeko third drug either vertex yet determin
combin bring regulatori review data nearli
equival tezacaftor small molecul drug correct genet
defect caus mutat cftr gene combin ivacaftor
potenti drug allow defect protein cell surfac stay open
longer improv chlorid transport shown impress efficaci
nearli patient includ previous difficult-to-treat het-min patient
one del mutat anoth minim function mutat mean
one allel produc defect cftr protein druggedth
produc protein correct use two corrector allow even better
correct protein fold brought cell surfac explain
basic scienc behind vertex key therapeut appendix link
think vertex could present data one corrector fall
data need determin tripl bring regul vertex recent
releas top-lin data tripl demonstr compar efficaci
tripl releas octob endpoint investor
expect vertex make decis asset move forward data set
molecul perform well see figur week het-min
homozyg patient vertex indic follow data compani
make decis asset brought forward push back file
tripl us europ
given excel data week confid tripl like get approv
open vertex cf patient excit tripl
believ market fairli price revenu upsid growth model see
increment sale het-min patient tripl like address
mutat amen treatment lumacaftor orkambi symdeko addit het-min
model increment sale het-min patient remaind captur
symdeko think less individu product sale overal
perform cf franchis align vertex approach give guidanc
give cf franchis sale number reimburs offer portfolio approach
mani govern outsid us expect full data one combin
mutat minim function absolut improv baselin week absolut improv baselin week charl martineau pm univers toronto
north american cystic fibrosi confer octob compani
indic plan publish/pres combin brought
forward regulatori review
saw upsid announc first tripl
believ full upsid tripl reflect share inde novemb
saw share increas releas tripl base
share appreci even decemb outperform ibb xbi
see figur highlight share weak data
second tripl releas disappoint move back
timelin fda ema submiss think clariti data
specif file could help support share near-term
result het-min
data result het-
min
data result het-
could see strength share around formal announc file
approv think vertex addit revenu het-min
patient total cf franchis sale
model tripleth cs approach
regardless tripl combin vertex decid move forward assum
approv us ou note tripl combin
three-drug regiment combin ivacaftor tezacaftor third correct vx-
combin like abl treat het-min popul one
mutat one minim function mutat also patient
elig kalydeco orkambi symdeko model assum patient
het-min treat tripl better quantifi increment
opportunitythu tripl estim may directli compar consensu
estim compar overal cf franchis sale vs consensu like
apples-to-appl comparison line vertex provid guidanc
per vertex approxim patient one mutat one
minim function mutat aka het-min ww address territori assum
us remaind ou price assum
price kalydeco per week wac annual cost appli
discount complianc result net annual cost per patient
tripl yet approv risk adjust sale probabl
success assum rel high penetr peak het-min popul
see peak sale reiter het-min patient model
homozyg residu function gate mutat kalydeco orkambi
symdeko build figur us het-min tripl combin build
tripl ou exclud franc uk assum het-min patient
outsid us approxim patient product
vertex cf portfolio model slower penetr tripl ou territori due
slower reimburs model approxim peak penetrationwhich could
higher see success england franc reimburs vertex product
price perspect assum similar ou price symkevi gross annual cost
gross-to-net discount complianc net annual cost per
patient us risk adjust sale tripl yet
approv figur ou tripl combin het-min build
includ sale franc uk base-row model address opportun
discuss approach model revenu countri
figur ou tripl combin het-min revenu build unadjust exclud uk franc
us market tripl minim cftr function total tripl gross list treatment gross list cost tripl sale market tripl minim cftr function tripl patient excl sale charl martineau pm univers toronto
limit competit patient least one mutat
like approv tripl vertex would cement domin posit
real player develop target therapi cf galapago
develop better corrector use ivacaftor data mix
galapago formal hand right octob homozyg
patient treat doublet potenti similar ivacaftor
corrector similar lumacaftor demonstr mean improv
week addit third corrector result addit
enhanc cftr activ glpg pr week orkambi produc
rel improv note efficaci typic seen earli
seen earli week good indic week
figur data falcon trial part
number patient
mean absolut improv
baselin week
subsequ two-week treatment tripl combin result addit
enhanc cftr activ
continu develop assetsw see competit
threat vertex cf franchis simpli put see asset inferior well
behind vertex data falcon trial bode well success
cf develop eventu approv could potenti see usag area
vertex therapi fulli reimbursed/access view would
headwind vertex cf sale long-term figur overview novel cf drug
develop
figur novel cf drug develop
vertex current portfolio treat cf mutationsto reach
remain differ therapeut approach like requir approv
tripl combin abl treat cf patient mutat
gate mutat homozyg mutat residu function mutat
one mutat one minim cftr function mutat essenti patient
least one mutat elig therapi see figur unfortun
compani believ potentiator/corrector therapi would work
remain mutat mani rare occur small
fraction patient treat remain patient compani believ either
gene-edit mrna approach would requir treat patent
therapeut ow pt studi ataluren nonsens mutat cfbut
trial fail show efficaci
figur cf popul treatabl vertex therapi
least one mutat except kalydeco
elig patient one mutat
cystic fibrosi like remain key cash flow gener vertex near-term
much vertex outperform thesi base continu upsid cf franchis
think consensu underestim cash flowsespeci potenti reimburs
agreement england franc forward price-to-earnings share screen
high vertex profit sinc enjoy signific growth near-
term think rel low forward ratio share suggest growth
fulli bake valuat rel less expens vs peer larg cap
biotech major pharma
vertex pipelin beyond cf pain crispr
limit credit current valuat free call option potenti meaning
vertex expand beyond cf program antitrypsin
defici pain hemoglobinopathi genom edit
formal includ valu non-cf pipelin valuat discuss
believ key program watch next year also
assum continu spend vertex dcf valuat impli valu
work even without formal project cash flow assets/program
review key program antitrypsin defici pain inhibitor
crispr gene edit sickl cell diseas beta thalassemia
small molecul correct
defici earli develop initi drug candid enter
clinic develop decemb
vertex develop small molecul corrector correct fold defect
protein encod gene vital protein protect lung
defici lead tissu damag proteolyt enzym elastas
patient diseas develop symptom indic pulmonari
emphysema patient also develop liver diseas due accumul
unsecret mutant protein accord publish report natur histori
diseas strongli depend cigarett smoke first four decad life
liver dysfunct primari health concern patient later life studi
less clear symptomat manifest diseas patient
smoke cigarett may rel normal life-span case sever
defici review differ genotyp next patient smoke
develop radiograph emphysema vs nonsmok
vertex literatur suggest could patient
defici us europ broadli defin address
market literatur suggest diseas may under-diagnos
common rare diseas see stoller et al link note current
diseas modifi therapi support therapi current avail
option patient aat-caus copd/ emphysema inhal bronchodil
steroid nih treatment recommend found link overal success
program could good size opportun vertex diseas
modifi therapi rel larg patient popul orphan diseas
estim success could peak opportun assum price
around per patient per year penetr
inherit autosom co-domin transmissionwith patient receiv
mutant gene parent accord vertex patient carri
singl point mutat gene accord up-to-d common
mutat allel gene caus point mutat hing region
molecul caus increas tendenc polymer
aggreg up-to-d high-level similar mutat
produc cftr protein misshapen fix small molecul
corrector patient compound heterozygos two differ mutat
genevari combin mutat differ risk lung
liver symptom see figur detail pre-clin data present vertex suggest
target patient allel variant use piz transgen mous
pre-clin studi produc defici plasma level less normal
us caucasian popul carrier
phenotyp would amen vertex current small molecul
approach includ null detect protein plasma
patient risk lung diseas suffer liver damag protein
made thu accumul liver tissu key phenotyp
dysfunct allel produc normal amount protein
function properli patient impair anti-elastas function activ excess
elastas shown contributor develop
figur characterist antitrypsin variant
null allel less normal concentr antitrypsin
preclin data suggest vertex small molecul corrector increas
circul level piz transgen mous level seen carrier
highlight preclin data demonstr first-gener small molecul
corrector may efficaci clinic trial see figur preclin work also suggest
small molecul corrector address patholog liver reduc
accumul misfold protein see figur expect potenti updat
program later
demkow van overveld fj role elastas pathogenesi chronic obstruct pulmonari diseas implic
pi allelecellular defectorgan affectedm mariou subtyp nonenonexchristchurchnonenonezintracellular accumul defect inhibit neutrophil elastaseliv lungmmaltonintracellular accumulationliv lungsiiyamaintracellular accumulationliv lungmheerlenintracellular degradationlungmprocidaintracellular degradationlungmminer springsintracellular degrad defect inhibit neutrophil elastaselungsintracellular degradationlungqogranit fallsstop codon mrna proteinemphysemaqoludwigshafenmrna present abnorm protein destabilizedliv lungqohongkongframeshift stop codon short protein intracellular accumulationearli onset emphysemaqoisola di procidadelet mrna proteinhigh risk emphysemaqoboltonstop codon mrna proteinhigh risk emphysemapittsburgsubstitutionbleed diathesi due chang protein antithrombin propertiesfimpair bind neutrophil elastasenorm serum antitrypsin level impair anti-elastas function activitynorm allelesdysfunct allelesnul allel defici allel associ intracellular degradationdefici allel associ intracellular charl martineau pm univers toronto figur circul piz transgen mous
model treat small molecul candid
pain
treat small molecul candid
pain program led also remain earli interest clinic data thu
far still mix data competitor target similar pathway make difficult
us full confid program
vertex current develop variou pain indic includ acut
pain follow bunionectomi neuropath pain osteoarthr pain given
recent focu develop non-opioid pain treatment welcom effortbut
believ clinic data must robust support pivot develop
could larg market could requir signific clinic trial invest note
vertex receiv break-through therapi design acut pain
indic fda will work vertex develop drug may
demonstr substanti improv avail therapi clinic signific
endpoint fda websit breakthrough therapi design link
select inhibitor could use pain literatur suggest specif
voltage-g sodium channel subtyp associ pain block
pain reduc liu et al link work similar pathway
limit success thu far recent vertex indic
engag on-going research discover/ develop addit inhibitor
potenti pain molecul januari investor present compani
said much recent pain programnot highlight data recent investor
present lead us believ develop work requir produc
viabl clinic candid regardless outlin progress clinic data
provid detail overview program
similar benefit opioid-bas therapi hydrocodon acetaminophen
phase trial design show non-inferior opioid-bas therapi
show statist signific benefit vs placebo reduc pain patient immedi
follow bunionectomi hour post-surgeri robust opioid therapi
see signific improv sum pain intens differ
hour see figur report top-lin releas safeti seem clean
patient arm complet treatment
discontinu due ae seriou report arm studi
common across arm nausea headach vomit dizzi
expect data phase dose rang trial near-term clinicaltri gov
indic trial complet februari link
figur phase acut pain
number patient
data phase small fiber neuropathi pain trial suggest good efficaci vx-
vs placebo small studi patient activ placebo saw
statist signific reduct pain caus small fiber neuropathi figur
safeti perspect trial indic well toler
patient activ group complet treatment placebo group
complet treatment saw higher number discontinu due
placebo group vs activ group vs patient patient activ arm experienc
seriou ae vs placebo arm common ae among patient treat vx-
headach patient vs placebo arm
figur phase small fiber neuropathi
number patient
mean chang baselin nr week
data older trial osteoarthr knee demonstr long-term
efficaci day although trial small limit detail top-lin
data trial patient clinicaltri gov link saw treatment effect
womac western ontario mcmaster univers osteoarthr index
pain scale assess pain across five activ scale use
patient-report outcom note trial patient activ arm
discontinu treatment vs placebo arm seen substanti
updat trial sinc top line data januari
overal seen interest data across variou phase trial
believ earli make call program either
back-up molecul note high unmet need treatment pain
especi light current opioid addict epidem us could
attract commerci opportun vertex also highlight pain develop
program difficult costli run see assess regeneron fasinumab
program on-going decad approv therapi
encourag fda award breakthrough therapi design absent full
phase data top line clear phase plan formal exclud sales/
commerci opportun valuat share
partnership crispr therapeut
develop program sickl cell diseas beta thalassemia
vertex enter collabor agreement crispr crsp
rate develop ex-vivo gene therapi treat sickl cell diseas
approach cystic fibrosi vertex paid crispr cash
provid addit convert loan proce
main program crispr partnership develop ex-
vivo gene therapi treat hemoglobinopathiesinclud beta-thalassemia sickl cell
diseas technolog use gene edit techniqu upregul
express gamma globin protein hemoglobin subunit commonli
present newborn infant symptom sickl cell beta-thalassemia
present infant typic high level fetal hemoglobin aim edit
genom patient hematopoiet stem cell upregul express
gamma globin protein give rise red blood cell contain hbf could
reduc symptom associ diseas remov
enhanc thought increas fetal hemoglobin
februari vertex announc first patient infus
phase clinic trial beta thalassemia clinicaltri gov link
compani specif see initi clinic data note
primari endpoint month post endpoint measur transfus reduct
least month think might stretch see clinic data
orlando fl would around month mark infus
might realist venu first patient enrol phase trial
sickl cell diseas februari infus expect healthi
donor saw increas hbf hematopoiet stem cell treat
note applic earli therapi
recent enter clinic crispr market cap
assign formal valu program dcf valuat vertex share
edit new could see competit sickl cell/ beta
thalassemia space highlight recent advanc acceleron bluebird bio
cover real competit indic
discuss ip note clinic use brought forward continu
litig settlement like occur across patent holder technolog
februari univers california grate foundat patent
gene edit could still face challeng licens requir
see begley univers california grant long-sought crispr patent
possibl reviv disput broad institut stat news februari
think pipelin repres good potenti expans beyond cf still
limit clinic data think current valuat exclud formal credit
review program note vertex capac expand pipelin
strateg acquisit tradit compani focus earlier-stag
asset crispr preclin develop could see acquisit
broader gene therapi focus platform later-stag asset could diversifi beyond
cf thesi predic earlier pipelin success acquisit thu
posit updat either area would surpris upsid
forecast vertex incom statement balanc sheet statement
project fy revenu bottom-lin
forecast non-gaap ep figur incom
statement balanc sheet found figur statement cash flow
found figur
incom statement sale residu tripl combin cf opportun ex cf opportun ex cf revenu product incom loss tax expense/ benefit tax incom cs averag share dilut ep dilut cs charl martineau pm univers toronto
balanc asset cash expens current current equip tax stockhold equitycurr liabil account leas oblig current term current term leas oblig exclud current leas oblig exclud current prefer paid-in comprehens stockhold liabil stockhold charl martineau pm univers toronto
figur vertex statement flow
statement activ net incom compens includ defer asset expens cash use oper invest cash use invest note payable/credit common issuanc exercis stock leas issuanc common stock cash use financ currenc decreas increas cash cash cash equival begin cash equival end charl martineau pm univers toronto
holt view vertex
run project holt valuat framework result
warrant valu per share target price
holt credit suiss proprietari methodolog compani analysi stock
select deliv object global consist view compani
holt use perform metric known return invest cfroi
adjust account distort compar econom perform across
sector region time appl appl basi holt valuat methodolog
base discount cash flow framework number distinguish featur
includ uniqu way calcul termin valu firm cost capit
base forecast holt dcf get warrant valuat per
share target price mainli due holt rel lower discount rate
util nomin wacc holt discount rate state real
term
note holt discount rate differ tradit method deriv wacc
holt discount rate forward-look market-deriv expect return asset
holt model self-consist system discount rate tune market price
long-term cash flow project holt use market impli discount rate
countri yield requir investor base current aggreg stock valuat
appli adjust compani specif leverag size act risk factor
refer holt us market discount rate long-term averag global
discount rate beyond earn holland matthew
beyond holt dcf framework appli mean revers methodolog
calcul termin valu assum cfroi discount rate fade gradual
long term averag asset growth fade reach averag growth
also run sensit analysi show vrtx valuat
sensit top line growth indic get target price holt impli
growth neg bp declin margin
charl martineau pm univers toronto figur holt analysi vertex
cs peer relationship vertex
peer global databas captur uniqu inform compani within
credit suiss coverag univers base relationship compani
custom supplier competitor databas built research analyst
insight regard relationship credit suiss cover compani global
compani form core peer databas also includ relationship
stock coverag figur
figur cs peer relationship map
author report evan seigerman would like acknowledg work
matthew terwelp md adrian garcia associ credit suiss larg cap
cystic fibrosi overview vertex medicin
cystic fibrosi disord caus genet defect cystic fibrosi transmembran conduct
regul cftr gene impact multipl system bodi common caus diseas morbid
mortal cf-relat pulmonari diseas howev organ system also involv includ pulmonary/lung
pancrea digest reproduct see figur core mani cell membran cftr protein
surfac allow transport chlorid ion cell maintain homeostasi lung
exampl balanc water chlorid ensur mucu line airway thin free flow patient
cf mucu thick sticki easili move sticki mucu build up caus caus
difficulti breath also trap virus bacteria caus increas rate infect patient cf either
defect cftr protein cell surfac open enough other reach cell surfac
clear product ribosom case patent dna contain mutat
nonsens mutat even allow product defect cftr protein
prior approv vertex therapi potenti address cf mutat life expect
cf patient approxim year surviv improv slowli usag inhal antibiot
 tobramycin case lung transplant exclud cftr modul therapi treatment cf involv
airway clearanc therapi infect prevent anti-inflammatori therapi bronchodil patient also treat
pancreat digest complic oral pancreat enzym supplement diet modif
therapi work extend life span cf patient address underli caus diseas
defect cftr protein
vertex therapi address underli caus cf either correct structur increas
channel activ defect cftr protein mutat produc cftr protein
amen treatment vertex therapi current avail investig nonsens splice mutat
vertex first therapi kalydeco ivacaftor act defect cftr protein cell surfac channel
small allow chlorid ion freeli flowthes call gate mutat gate chlorid ion
close ivacaftor act allow channel gate stay open see figur allow balanc water
chlorid ion restor produc normal mucu airway kalydeco work patient
cftr protein cell surfac patient littl cftr caus mutat creat misfold cftr
protein addit drug known corrector need restor normal function
figur kalydeco mechan action
sever trial studi impact ivacaftor formal includ data one
pivot trial examin drug patient year older least one mutat figur
see abl rapidli increas percent predict forc expiratori volum second
clear separ placebo week continu week endpoint statist signific
improv vs placebo week measur lung function look reduct
sweat chlorid concentr figur anoth measur cftr function see rapid maintain reduct
sweat chlorid patient treat ivacaftor maintain week week patient treat
ivacaftor also less like experi pulmonari exacerb week week see kaplan-mei
plot figur safeti profil ivacaftor clean fewer exacerb activ arm due therapi
similar across activ placebo arm figur
chang baselin
figur strive chang baselin sweat
 seriou advers event ae occur subject either groupsubject seriou exacerb physician respiratori tract incid either treatment group differ rel charl martineau pm univers toronto
vertex corrector therapi lumacaftor tezacaftor help misfold cftr protein reshap
product allow protein reach cell surfac patient mutat cftr protein form
shape correctli defect caus cell destroy remov defect protein proteasom
abl reach cell surfac result littl cftr protein membran corrector allow
cftr protein fold correctli subsequ mark destruct allow reach cell
membran cftr protein still need potenti help increas channel activ channel
correct protein still potenti compromis lumacaftor first approv corrector combin
ivacaftor orkambi vertex subsequ develop second corrector tezacaftor improv profil vs
lumacaftor use combin ivacaftor market symdeko us/canada symkevi outsid
north america drug use treat patient two mutat symdeko also use
treat patient residu function mutat figur detail moa potenti corrector
patient littl cftr protein cell surfac caus mutat
figur impact cftr potenti corrector
orkambi approv use data traffic transport clinic trial support year
dose improv less saw ivacaftor monotherapi trial highlight
differ patient popul homozyg vs gate mutat week
traffic/transport trial saw statist signific improv absolut chang patient
treat dose investig combin lumacaftor ivacaftor ultim lower dose
lumacaftor approv combin ivacaftor week saw transport
traffic respect improv vs declin transport traffic respect
patient treat placebo lower dose lumacaftor produc similar result traffic transport
respect see figur also saw consist combin drug effect across multipl paramet
traffic transport trial see figur trial saw statist signific reduct event
requir hospit iv antibioticstwo addit way demonstr impact patient symptom
overal cost diseas health care system figur
figur subgroup analys show consist
week treatment
charl martineau pm univers toronto figur signific reduct pulmonari exacerb requir hospit iv antibiot
note pool analysi traffic transport
safeti profil lumacaftor/ivacaftor suffici regulatori approv note
concern liver toxic report worsen liver function report patient per orkambi pi link
also highlight respiratori event chest discomfort dyspnea respir abnorm observ
commonli patient initi orkambi compar receiv placebo event led
drug discontinu seriou particularli patient advanc lung diseas percent predict
orkambi pi real world usag chest tighten refer throughout report caus
discontinu orkambi includ pool safeti data traffic/transport figur liver
function test elev trial figur
figur summari liver function test
symdeko improv efficaci orkambi better lung function improv week
measur better side-effect profil evolv trial publish nejm link saw
absolut improv patient treat tez/iva vs placebo trial also hit key
secondari endpoint exclud absolut chang week time point probabl long enough
show differ see figur safeti perspect combin tez/iva potenti better profil
vs orkambi low incid abnorm find liver-funct test patient treat tez/iva also fewer
respiratori event one key issu orkambi patient tez/iva vs placebo
summari safeti find evolv trial symdeko pi found
 treatment due seriou pulmonari frequent activ arm placebolum qd/ iva iva common ast uln tb bilirubin tb qd/ iva lum iva ast u/l total bilirubin umol/l alt charl martineau pm univers toronto
figur evolv trial primari secondari endpoint
primari secondari efficaci endpoint
number patient
absolut chang baselin percentag predict week
rel chang baselin percentag predict week
pulmonari exacerb week number event
absolut chang baselin week ci
absolut chang baselin cfq respiratori domain score week
absolut chang baselin bmi-for-ag score baselin week
absolut chang baselin sweat chlorid concentr week
data least-squar mean confid interv except number patient pulmonari exacerb week number event
annual estim event rate shown differ least-squar mean differ tezacaftor-ivacaftor group placebo group basi mixed-effect
model repeat measur except number pulmonari exacerb rate ratio shown valu between-group comparison case valu
provid comparison list test hierarchi statist signific broke denot body-mass index
between-group differ express rate ratio analysi base neg binomi regress model week per year use calcul event rate
data includ patient younger year age baselin patient placebo group tezacaftor-ivacaftor group
number patient
number patient percent
advers event relat trial regimen
advers event accord maximum sever
grade advers event
seriou advers event relat trial regimen
advers event lead discontinu
advers event lead death
infect pulmonari exacerb cystic fibrosi
determin related trial regimen made investig
one patient tezacaftor-ivacaftor group life-threaten seriou advers event hemoptysi
common advers event occur patient either trial group
tripl combin therapi combin ivacaftor tezacaftor third-gener corrector ether vx-
abl potenti address patient one mutat one minim function
mutat patient known sever case cf one allel cftr mutat make
misfold cftr protein caus mutat mutat make cftr protein minim
function caus stop mutat result patient even fewer potenti cftr protein
correct transport cell membran patient residu function mutat second allel produc
cftr protein function thought milder phenotyp inde green et al link show
patient minim function mutat typic prone infect vs patient residu function
mutat hr rang depend pathogen studi experi mean patient
minim function mutat much like develop infect particular pathogen author note
studi demonstr differ hr patient minim function mutat residu function
mutat patient decreas lung function longer benefit residu function mutat vs
minim function mutat suggest cf progress mutat matter less prognosi still biolog
empir evid suggest patient minim function mutat wors especi healthier
potenti amen treatment vertex therapi figur detail
charl martineau pm univers toronto figur infect risk cftr mutat type
adjust infect number cultur
first infect one posit cultur organ
chronic infect three posit cultur within month posit cultur least month last posit cultur
multipl infect three posit cultur organ
persist infect least one posit cultur organ two three consecut year
tripl combin therapi use next-gener corrector combin tezacaftor ivacaftor produc
enhanc efficaci difficult-to-treat patient ad efficaci third corrector allow
misfold cftr protein produc one copi cftr gene mutat correctli fold
reach cell membran cftr protein produc cftr gene minim function mutat still
defect untreat either corrector use potenti still requir increas channel activ
cftr protein reach cell surfac review clinic data tripl fundament
consider report link
total posit includ analysi minim function class posit residu function class posit adjust hazard ratio pseudomona aeruginosafirst pseudomona aeruginosafirst fumigatusfirst charl martineau pm univers toronto
jeffrey leiden chairman chief execut offic
dr leiden held posit chief execut offic presid sinc februari join ceo
designe decemb member board director sinc juli chairman
board director sinc may serv lead independ director octob decemb
manag director claru ventur life scienc ventur capit firm januari
presid chief oper offic pharmaceut product group member
board director abbott laboratori held sever academ
appoint includ rawson professor medicin patholog chief cardiolog director
cardiovascular research institut univers chicago elkan blout professor biolog scienc
harvard school public health professor medicin harvard medic school elect member
american academi art scienc institut medicin nation academi scienc
serv director massachusett mutual life insur compani director
non-execut vice chairman board shire plc specialti biopharmaceut compani januari
receiv ph degre univers chicago
david altshul execut vice presid global research chief scientif offic
dr altshul execut vice presid global research chief scientif offic sinc januari
member board director may decemb one four found member
broad institut research collabor harvard massachusett institut technolog whitehead
institut harvard hospit serv director institut program medic popul
genet decemb institut deputi director chief academ offic
decemb join faculti harvard medic school massachusett gener hospit
held academ rank professor genet medicin decemb serv
adjunct professor biolog mit decemb earn mit ph
harvard univers harvard medic school complet clinic train intern medicin
endocrinolog diabet metabol massachusett gener hospit
stuart arbuckl execut vice presid chief commerci offic
mr arbuckl execut vice presid chief commerci offic sinc septemb prior
held multipl commerci leadership role juli august work
biopharmaceut industri sinc includ year glaxosmithklin held sale
market role increas respons medicin aim treat respiratori metabol musculoskelet
cardiovascular diseas serv member board director cerulean pharma inc june
juli serv member board director inc sinc januari
hold bsc pharmacolog physiolog univers leed
reshma kewalramani execut vice presid chief medic offic
dr kewalramani execut vice presid chief medic offic sinc april senior vice
presid late develop februari april august januari serv role
increas respons amgen inc recent vice presid global clinic develop nephrolog
metabol area vice presid medic organ industri repres
fda endocrin metabol drug advisori committe complet internship resid intern
medicin massachusett gener hospit fellowship nephrolog massachusett gener hospit
brigham women hospit combin program hold boston univers
boston univers school medicin
michael parini execut vice presid chief legal administr offic
mr parini execut vice presid chief legal administr offic sinc januari
join vertex serv variou role increas respons pfizer inc recent senior vice
presid associ gener counsel prior attorney akin gump strauss hauer feld
 hold georgetown univers georgetown univers law center
amit sachdev execut vice presid chief regulatori offic
mr sachdev execut vice presid chief regulatori offic sinc januari serv
execut vice presid polici access valu octob decemb join
vertex senior vice presid led govern affair public polici activ well patient
advocaci program prior serv execut vice presid biotechnolog industri
organ deputi commission polici fda also serv sever senior
posit prior fda serv major counsel committe commerc unit
state hous repres practic law chemic manufactur associ subsequ
law firm rope gray llp hold carnegi mellon univers emori univers school
law
charl wagner execut vice presid chief offic
mr wagner join vertex execut vice presid chief offic prior join vertex
execut vice presid financ cfo ortho clinic diagnost inc carlyl group portfolio compani prior
serv cfo bruker corpor progress softwar corpor millipor corpor addit
corpor financ role serv advisor bain compani lybrand april
august serv director chairman audit committe start genet inc previous
serv director bruker corpor member audit committe august june hold
 account boston colleg harvard busi school
paul silva senior vice presid corpor control
mr silva senior vice presid corpor control sinc april januari appoint
interim chief offic join august senior director account oper vice
presid corpor control septemb april prior vice presid
intern report iron mountain incorpor juli august consult iron mountain
financ depart april juli financ director bioscienc technolog divis
thermo electron corpor april hold account assumpt colleg
compani mention price
evan seigerman certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
